{"schema_version":"secwatch.filing_event.v1","accession":"0001771910-25-000006","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.941503+00:00","generated_at":"2026-05-17T14:45:22.739031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ADC Therapeutics Q2 net loss widens to $56.6M; completes $100M PIPE, cuts workforce 30%","bullets":["Q2 product revenue $18.1M (+6% YoY); net loss $56.6M ($0.50/share) vs $36.5M loss ($0.38) in Q2 2024.","Completed $100M PIPE with $93.1M net proceeds; cash $264.6M, expected runway into 2028.","LOTIS-7 (ZYNLONTA+glofitamab) showed 93.3% ORR, 86.7% CR in r/r DLBCL; expansion to 100 patients underway.","Strategic restructuring: discontinuing early solid tumor programs, shutting UK facility, workforce reduction ~30% by Sep 2025.","LOTIS-5 Phase 3 on track to reach PFS events by end of 2025; sBLA filing expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001771910-25-000006","json":"https://secwatch.observer/filing/0001771910-25-000006.json","markdown":"https://secwatch.observer/filing/0001771910-25-000006.md","text":"https://secwatch.observer/filing/0001771910-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000177191025000006/0001771910-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000177191025000006/adc-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:45:22.739031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}